Altos, headed by Hal Barron, MD CEO and Rick Klausner, MD CSO and founder launched in January 2022 with three billion dollars in funding. The new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos’ mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. Altos has a remarkable line of scientists and leaders.